Abstract
Neurofibromatosis 1 (NF1) is a common, fully penetrant autosomal dominant disease. The clinical course is generally progressive but highly variable, and the pathogenesis is poorly understood. We studied statistical associations among 13 of the most common or important clinical features in data from four separate sets of NF1 patients: a "developmental sample" of 1,413 probands from the NNFF International Database, an independent "validation sample" of 1,384 probands from the same database, 511 affected relatives of these probands, and 441 patients from a population-based registry in northwest England. We developed logistic regressive models for each of the 13 features using the developmental sample and attempted to validate these models in the other three samples. Age and gender were included as covariates in all models. Models were successfully developed and validated for ten of the 13 features analysed. The results are consistent with grouping nine of the clinical features into three sets: (1) café-au-lait spots, intertriginous freckling and Lisch nodules; (2) cutaneous, subcutaneous and plexiform neurofibromas; (3) macrocephaly, optic glioma and other neoplasms. In addition, three-way interactions among café-au-lait spots, intertriginous freckling and subcutaneous neurofibromas indicate that the first two groups are not independent. Our studies show that some individuals with NF1 are more likely than others to develop certain clinical features of the disease. Some NF1 features appear to share pathogenic mechanisms that are not common to all features.
Similar content being viewed by others
References
Allanson J, Upadhaya M, Watson G, Partington M, MacKenzie A, Lahey D, MacLeod H, Sarfarazi M, Broadhead W, Harper P, Huson S (1991) Watson syndrome: is it a subtype of type 1 neurofibromatosis? J Med Genet 28:752–756
Bajenaru M, Donahoe J, Corral T, Reilly K, Brophy S, Pellicer A, Gutmann D (2001) Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 33:314–323
Bolande R (1974) The neurocristopathies: a unifying concept of disease arising in neural crest development. Hum Pathol 5:409–429
Burger P, Scheithauer B (1994) Atlas of tumor pathology: tumors of the central nervous system. Armed Forces Institute of Pathology, Washington, D.C.
DeBella K, Szudek J, Friedman JM (2000) Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 105:608–614
DiMario FJ Jr, Ramsby GR, Burleson JA (1999) Brain morphometric analysis in neurofibromatosis 1. Arch Neurol 56:1343–1346
Easton D, Ponder M, Huson S, Ponder B (1993) An analysis of variation in expression of neurofibromatosis (NF) type I (NFI): evidence for modifying genes. Am J Hum Genet 53:305–313
Eisenbarth I, Beyer K, Krone W, Assum G (2000) Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. Am J Hum Genet 66:393–401
Fitzpatrick TB (1981) Melanin synthesis pathways in the pathogenesis of neurofibromatosis. Adv Neurol 29:209–211
Friedman J, Birch P (1997a) Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 70:138–143
Friedman JM, Birch P (1997b) An association between optic glioma and other tumours of the central nervous system in neurofibromatosis type 1. Neuropediatrics 28:131–132
Friedman J, Greene C, Birch P (1993) National Neurofibromatosis Foundation International Database. Am J Med Genet 45:88–91
Friedman JM, Riccardi VM (1999) Clinical and epidemiological features. In: Friedman JM, Gutmann DH, MacCollin M, Riccardi VM (eds) Neurofibromatosis : phenotype, natural history, and pathogenesis. Johns Hopkins University Press, Baltimore, pp 29–86
Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51–57
Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A (1999) Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 18:4450–4459
Gutmann D, Wu Y, Hedrick N, Zhu Y, Guha A, Parada L (2001) Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Hum Mol Genet 10:3009–3016
Hamill P, Drizd T, Johnson C, Reed R, Roche A (1977) NCHS growth curves for children birth-18 years. United States. Vital Health Stat 11:1–74
Harkin J, Reed R (1969) Atlas of tumor pathology: tumors of the peripheral nervous system. Armed Forces Institute of Pathology, Washington, D.C., pp 67–100
Hosmer D, Lemeshow S (1989) Applied logistic regression. Wiley, Toronto
John A, Ruggieri M, Ferner R, Upadhyaya M (2000) A search for evidence of somatic mutations in the NF1gene. J Med Genet 37:44–49
Kleinbaum D (1992) Logistic regression: a self-learning text. Springer, New York
Leppig K, Kaplan P, Viskochil D, Weaver M, Ortenberg J, Stephens K (1997) Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet 73:197–204
McGaughran JM, Harris DI, Donnai D, Teare D, MacLeod R, Westerbeek R, Kingston H, Super M, Harris R, Evans DG (1999) A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 36:197–203
NIH (1988) Neurofibromatosis: conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575–578
Perry H, Font R (1982) Iris nodules in von Recklinghausen's neurofibromatosis: Electron microscopic confirmation of their melanocytic origin. Arch Ophthalmol 100:1635–1640
Pietruschka G (1961) Zur symtomatic der neurofibromatosis multiplex nach von Recklinghausen im Bereich des Sehorgans. Med Bild 4:8–11
Rasmussen SA, Overman J, Thomson SA, Colman SD, Abernathy CR, Trimpert RE, Moose R, Virdi G, Roux K, Bauer M, Rojiani AM, Maria BL, Muir D, Wallace MR (2000) Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 28:425–431
Riva P, Corrado L, Natacci F, Castorina P, Wu B, Schneider G, Clementi M, Tenconi R, Korf R, Larizza L (2000) NF1microdeletion syndrome: refined FISH characterization of sporadic and familial deletions with locus-specific probes. Am J Hum Genet 66:100–109
Said S, Yeh T, Greenwood R, Whitt J, Tupler L, Krishnan K (1996) MRI morphometric analysis and neuropsychological function in patients with neurofibromatosis. Neuroreport 7:1941–1944
SAS Institute (1996) SAS release 6.12, Carey, North Carolina
Serra E, Ars E, Ravella A, Sanchez A, Puig S, Rosenbaum T, Estivill X, Lazaro C (2001) Somatic NF1 mutational spectrum in benign neurofibromas mRNA splice defects are common among point mutations. Hum Genet 108:416–29
Szudek J, Birch P, Riccardi VM, Evans DG, Friedman JM (2000) Associations of clinical features in neurofibromatosis 1 (NF1). Genet Epidemiol 19:429–39
Weston J (1981) The regulation of normal and abnormal neural crest cell development. Adv Neurol 29:77–95
Zehavi C, Romano A, Goodman R (1986) Iris (Lisch) nodules in neurofibromatosis. Clin Genet 29:51–55
Acknowledgements
We thank Patricia Birch, Dr. Harry Joe and the National Neurofibromatosis Foundation International Database Participants for their contributions. Supported in part by the Department of the Army, USAMRMC, grant number NF960003.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
The first step in developing the model for each of the NF1 clinical features was to treat the selected feature as the response variable (Y) as a function of age in a logistic regression equation:
where p(1| x) is Pr(Y=1| covariates x). Maximum likelihood techniques were used to generate parameter estimates (SAS Institute 1996). Linearity in the logit was examined in each model, and age was transformed when necessary to meet the requirement of linearity in the logit.
where
At AGE = 0, the value of this function is α + β1. For negative values of β1, the value of AGETRF approaches α as AGE gets larger. This function approximates the frequency-by-age curves of the NF1 features considered in this study (DeBella et al. 2000). It was necessary to use this transformation of AGE to maintain linearity of the logit for most outcome variables in this study.
At the second stage, a series of bivariate analyses was performed using the equation
where each of the 13 features was set in turn as the response variable (Y), and AGETRF and one of the 12 remaining features ( x) were used as explanatory variables to screen for potential main effects. Variables with parameters (β values) with P <0.2 were included as explanatory variables (x i values) in multivariate analyses at the third stage. AGETRF and gender were included as covariates in all of these third stage multivariate models:
Following maximum likelihood estimation of the parameters in the multivariate model, the importance of each explanatory variable was reassessed at the fourth stage. Explanatory variables with parameters greater than zero with P <0.2 were used to refit the model, and interaction terms (δ values) among the explanatory variables were considered by forward selection. For example,
Interpretation
The strength of interaction between the response variable (Y) and an explanatory variable ( x 1 ) in a univariate model is measured by β 1 . Subjects with variable x 1 coded as "present" are exp( β 1 ) times more likely also to have feature Y than are subjects with feature x 1 absent. The strength of interaction between Y and explanatory variables ( x 1 and x 2 ) in a bivariate model is measured by β 1 , β 2 , and δ 1 . Subjects with variables x 1 and x 2 present are exp( β 1 + β 2 + δ 1 x1x2) times more likely also to have the response variable.
Rights and permissions
About this article
Cite this article
Szudek, J., Evans, D.G. & Friedman, J.M. Patterns of associations of clinical features in neurofibromatosis 1 (NF1). Hum Genet 112, 289–297 (2003). https://doi.org/10.1007/s00439-002-0871-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00439-002-0871-7